Stocks · News reference

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Aug 26, 2026, 4:24 PMBenzinga Newsdesk

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 31, 2026, 9:21 PMSEC EDGAR
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-08-31 AccNo: 0001193125-26-377073 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
JAZZ
BenzingaAug 31, 2026, 5:27 PMBenzinga Newsdesk
Jazz Pharmaceuticals shares are trading higher after the company announced second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial.
JAZZ
BenzingaAug 31, 2026, 10:04 AMBenzinga Newsdesk
Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
JAZZ
BenzingaAug 27, 2026, 6:23 AMBenzinga Newsdesk
Jazz Pharmaceuticals Prices Upsized $1.1B Offering Of 1.875% Exchangeable Senior Notes Due 2032, Announces $225.0M Concurrent Share Repurchase At $249.29 Per Share
JAZZ